Spiegel A M, Gerner R H, Murphy D L, Aurbach G D
J Clin Endocrinol Metab. 1976 Dec;43(6):1390-3. doi: 10.1210/jcem-43-6-1390.
To test the hypothesis that lithium is a general inhibitor of hormone-activated adenylate cyclase, we infuse parathyroid hormone (PTH) into human subjects prior to and during lithium carbonate administration. PTH infusion caused a significant increase in urinary cyclic AMP and urinary phosphate excretion. There was no significant difference in these responses in the lithium compared to the control period. In four patients with primary hyperparathyroidism, lithium had no significant effect on serum calcium or phosphate or on tubular reabsorption of phosphate. The data do not substantiate the hypothesis that lithium (at therapeutic concentrations) is a general inhibitor of hormonally-activated adenylate cyclase, nor do they support its potential clinical utility in primary hyperparthyroidism.
为了检验锂是激素激活型腺苷酸环化酶的通用抑制剂这一假设，我们在给予碳酸锂之前及期间，向人体受试者输注甲状旁腺激素（PTH）。输注PTH导致尿中环磷酸腺苷（cAMP）及尿磷排泄显著增加。与对照期相比，锂治疗期间这些反应无显著差异。在4例原发性甲状旁腺功能亢进患者中，锂对血清钙、磷或肾小管对磷的重吸收无显著影响。这些数据既不能证实锂（治疗浓度时）是激素激活型腺苷酸环化酶的通用抑制剂这一假设，也不支持其在原发性甲状旁腺功能亢进中的潜在临床应用价值。
